Oncology

A leukemia clinical pharmacy specialist delves into the significance of educating patients on treatments and serving as a resource for both patients and health care providers.

In addition, patients who were treated with liso-cel therapy had a higher average life expectancy and QALYs, compared to those who were treated with standard care.

The pharmacist can assist with managing drug interactions, patient education, therapy selection, physician education, and more.

Compared to standard of care TKIs, asciminib also presented favorable safety and tolerability profiles with fewer reported AEs among patients.

Individuals with ischemic stroke that resided in areas with an indoor radon concentration greater than 4 pCi/L had an increased risk of developing clonal hematopoiesis of indeterminate potential.

The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

In the ambulatory setting, oncology pharmacists independently prescribe medications to support and manage therapy toxicities for cancer patients.

The report allows management to provide guaranteed assessments throughout the screenings that could aid early detection, diagnosis, and lung cancer treatment.

Nearly 75% of patients who had an initial complete response with mosunetuzumab maintained that complete response after 3 years.

The prospective observational study assessed a 2-year increasing lung cancer diagnosis risk, lung cancer characteristics, and the overall survival between LNP and LDCT screening.

Eliminating certain factors within the GRN resulted in the network shutting down, potentially leading to cancer cell death due to an inability to replicate, according to the study authors.

New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.

This study showed the importance of a multidisciplinary team’s expertise to investigate a clinical inquiry beyond the scope of the clinicians’ skillset and their access to necessary technology.

There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.

Investigators found that those who used statins post-breast cancer diagnosis had a lower risk of breast cancer death when the median total cholesterol decreased.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

In the Augment-101 phase 2 study, 63% of patients experienced overall response rate with revumenib.

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

From newsworthy moments to groundbreaking research, these were the most-read oncology-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most watched videos on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most listened-to podcasts on Pharmacy Focus in 2023.

From newsworthy moments to groundbreaking research, these were the most-read reimbursement-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read skin cancer-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.

The CAR T-cell therapy improved relative overall survival by more than a third compared to standard of care.

Expert discusses positive, real-world findings from a claims-based study looking at this therapeutic.

The therapy sustained IDFS benefit compared with ET alone.